Drug Discovery for Neurodegeneration

神经退行性疾病的药物发现

基本信息

批准号：
7806086
负责人：
Howard M. Fillit
金额：
$ 4万
依托单位：
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-15 至 2009-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7806086
关键词：
Academia Address Alzheimer&apos s Disease Amyotrophic Lateral Sclerosis Area Basic Science Development Discipline Disease District of Columbia Drug Industry Education Foundations Goals Grant Huntington Disease Incidence Industry Information Resources Journals Knowledge Learning Minority Nerve Degeneration Neurodegenerative Disorders Orphan Parkinson Disease Participant Peer Review Pharmaceutical Chemistry Pharmaceutical Preparations Phase Process Public Health Publishing Research Research Personnel Resources Schedule Scientist Services Technology Transfer Time Training Translating U-Series Cooperative Agreements United States National Institutes of Health Woman Work drug discovery graduate student meetings nervous system disorder next generation novel therapeutics pre-clinical prevent programs public health relevance public-private partnership skills symposium

项目摘要

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation (ADDF) requests a U13 Cooperative Agreement grant in support of its Drug Discovery for Neurodegeneration conference, scheduled for February 9-10, 2009 in Washington, DC. The purpose of the meeting is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutics. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside of the pharmaceutical industry to learn about these processes. The goals of this didactic conference are clearly consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; to provide networking opportunities for these scientists to exchange ideas and resources; and to ultimately publish the proceedings in a peer-reviewed, open access scientific journal. This two-day conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will address the barriers and challenges associated with the following sub-topics: Basics of Medicinal Chemistry; Hits & Leads: Early Phases of Drug Discovery; Pre-Clinical Proof-of-Concept & Development; Issues in Technology Transfer; Ask the Experts (breakout session); and Resources and Services for Advancing Drug Discovery. Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis and 'Orphan' neurological diseases will be included in the program. Sessions will consist of 3 to 5 presentations with ample time for Q&A. With respect to the public-private partnership initiative of the Roadmap, ADDF will invite 26 internationally recognized scientists from academia, industry and NIH to serve as chairs or speakers. It is anticipated that this conference will serve 150 scientists from diverse backgrounds, including women, minorities, young/junior investigators and graduate students. PUBLIC HEALTH RELEVANCE: The public health problem ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis. By offering this conference, ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying therapies.

描述（由申请人提供）：阿尔茨海默病药物发现基金会 (ADDF) 请求 U13 合作协议拨款，以支持定于 2009 年 2 月 9 日至 10 日在华盛顿特区举行的神经退行性疾病药物发现会议。会议的目的是通过培训下一代科学领导者将基础研究转化为新型疗法的过程，推进神经退行性疾病的药物发现。需要对此主题进行正式教育，因为该研究领域存在有记录的知识差距，并且制药行业之外很少有机会了解这些过程。这次教学会议的目标显然与 NIH 的路线图一致：弥合药物发现和神经退行性疾病方面的知识差距；汇集跨学科科学家，激发结合技能和学科的新方法；为这些科学家提供交流想法和资源的交流机会；并最终在经过同行评审的开放获取科学期刊上发表论文集。这次为期两天的会议将为与会者提供有关创造治疗和预防神经退行性疾病的新药的基础知识和资源。它将解决与以下子主题相关的障碍和挑战：药物化学基础知识；热门与领先：药物发现的早期阶段；临床前概念验证和开发；技术转让问题；询问专家（分组会议）；以及促进药物发现的资源和服务。阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症和“孤儿”神经系统疾病将被纳入该计划。会议将包括 3 至 5 场演讲，并有充足的问答时间。关于路线图的公私合作倡议，ADDF将邀请来自学术界、工业界和NIH的26位国际知名科学家担任主席或发言人。预计本次会议将为来自不同背景的 150 名科学家提供服务，包括女性、少数族裔、年轻/初级研究人员和研究生。公共健康相关性：ADDF 寻求解决的公共健康问题是减少神经退行性疾病的发病率，例如阿尔茨海默病、帕金森病、亨廷顿病和肌萎缩侧索硬化症。通过举办这次会议，ADDF 将增加科学家对药物发现过程的了解，并促进他们共同努力开发商业上可行且有效的疾病修饰疗法。